Glucagon like peptide-1 receptor agonists may ameliorate the metabolic adverse effect associated with antiretroviral therapy

Çulha, Mehmet Gökhan; İnkaya, Ahmet Çağkan; Yıldırım, Emre; Ünal, Serhat; Şerefoğlu, Ege Can

doi:10.1016/j.mehy.2016.07.016

Cited by 6 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reasons for an elevated risk of ASCVD among people living with HIV remains relatively poorly understood, but they are likely to be multifactorial ( 16 ). In the absence of randomized clinical trials or hypothesis-testing mechanistic studies, it is only possible to speculate that GLP-1 RAs can contribute to reduce the increased CV risk in subjects with HIV via “glycemic” and “extra- glycemic” actions including a beneficial effect on blood pressure, lipid profile, body fat, insulin resistance, and inflammation among the many ones ( 17 ).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report

et al. 2022

View full text Add to dashboard Cite

BackgroundType 2 diabetes (T2D) is a common comorbidity in people living with HIV (PLWH). Anti-hyperglycemic treatment in PLWH is still a challenge, and no randomized controlled studies using new glucose-lowering agents are currently available.Case DescriptionA 55-year-old-women was admitted to our Diabetes Unit because of hyperosmolar hyperglycemic state (HHS) and sepsis. The medical history included HIV infection and insulin-treated diabetes. On clinical examination, the lady appeared dehydrated with dry buccal mucosa, tachycardia, altered mental status, genital infection, and fever. On admission, plasma glucose was 54.5 mmol/L, HbA1c 155 mmol/mol, osmolarity 389.4 mOsm/kg, bicarbonate 24.6 mmol/L with no detectable serum ketones. The patient was treated with i.v. fluid and insulin, and antibiotic therapy commenced. Upon HHS and sepsis resolution, a basal-bolus insulin therapy was implemented that was followed by significant improvement of daily glucose profiles and progressive reduction of insulin requirement until complete discontinuation. A low dose of metformin plus linagliptin was started. Since a severe atherosclerotic disease was diagnosed, a GLP-1 receptor agonist, dulaglutide, was added to metformin upon linagliptin withdrawal with maintenance of good glycemic control, treatment adherence and amelioration of quality of life and no side effects.ConclusionThis case suggests that GLP-1 receptor agonist therapy may be effective and safe for treatment of T2D with high cardiovascular risk in PLWH, supporting the need of clinical trials directly assessing the safety and the efficacy of GLP-1 receptor agonist in these individuals.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Generally, the hypoglycemic effects of GLP-1 agonists improve the immune status in diabetic patients to counteract the microbial infections. The associated metabolic activities of these drugs may be helpful in the treatment of human immunodeficiency virus (HIV)-associated metabolic adverse effects[ 212 ], and PEGylated exendin-4 has the potential to treat sepsis[ 213 ].…”

Section: Glp-1 Agonistsmentioning

confidence: 99%

Anti-diabetics and antimicrobials: Harmony of mutual interplay

Hegazy¹,

Rajab²,

Lila³

et al. 2021

WJD

View full text Add to dashboard Cite

Diabetes is one of the four major non-communicable diseases, and appointed by the world health organization as the seventh leading cause of death worldwide. The scientists have turned over every rock in the corners of medical sciences in order to come up with better understanding and hence more effective treatments of diabetes. The continuous research on the subject has elucidated the role of immune disorders and inflammation as definitive factors in the trajectory of diabetes, assuring that blood glucose adjustments would result in a relief in the systemic stress leading to minimizing inflammation. On a parallel basis, microbial infections usually take advantage of immunity disorders and propagate creating a pro-inflammatory environment, all of which can be reversed by antimicrobial treatment. Standing at the crossroads between diabetes, immunity and infection, we aim in this review at projecting the interplay between immunity and diabetes, shedding the light on the overlapping playgrounds for the activity of some antimicrobial and anti-diabetic agents. Furthermore, we focused on the anti-diabetic drugs that can confer antimicrobial or anti-virulence activities.

show abstract

“…The only formally indicated pharmacologic intervention to reduce visceral adiposity in PWH is tesamorelin [12], which has been shown to lead to an 18% reduction of visceral adipose tissue (VAT). The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) [13] and other pharmacologic obesity treatments are gaining interest but are now currently being studied in PWH. Nonpharmacologic interventions, such as diet and exercise, are officially recommended for PWH who gain greater than 5% body weight [14].…”

mentioning

confidence: 99%

The importance of exercise and physical activity in older adults with HIV

Lee

2023

Aids

View full text Add to dashboard Cite

Glucagon like peptide-1 receptor agonists may ameliorate the metabolic adverse effect associated with antiretroviral therapy

Cited by 6 publications

References 41 publications

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report

Anti-diabetics and antimicrobials: Harmony of mutual interplay

The importance of exercise and physical activity in older adults with HIV

Contact Info

Product

Resources

About